trial
as of 2026-07-01Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia
NCTId NCT04010305
at a glance
Phase 1 · Completed
Enrollment 135 (actual)
Sponsored by BioXcel Therapeutics Inc
Primary completion 2019-07-31
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
135 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2019-05-22
Primary completion
2019-07-31
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
BioXcel Therapeutics IncLead Sponsor
Cognitive Research CorporationCollaborator
Sites
12 total
Little Rock, United StatesCerritos, United StatesLemon Grove, United StatesLong Beach, United StatesOrange, United StatesMiami Lakes, United StatesAtlanta, United StatesGaithersburg, United StatesFlowood, United StatesBerlin, United StatesAustin, United StatesRichardson, United States
Facts & assertions
4 sourced
Enrollment
135
Phase
PHASE1
Primary Completion Date
2019-07-31
Status
COMPLETED
relationships
The graph out of here
lead_sponsor
company
collaborator
indication